Sandbox Reserved 1470
From Proteopedia
(Difference between revisions)
Line 6: | Line 6: | ||
The protein being studied in this article is <scene name='79/799598/Cartoon_view_of_kgp/3'>KGP</scene> <ref>PMID:25266723</ref>. This cysteine peptidase is a major virulence factor for the periodontopathogen ''Porphyromonas gingivalis''. KGP works by cleaving many constituents of human connective tissue which leads to decreased bacterial activity and chronic inflammation in the gums. It contains a catalytic triad of cysteine, histidine, and aspartic acid. The histidine and aspartic acid residues in the catalytic triad use acid base chemistry catalysis to form a covalent intermediate with the cysteine. The intermediate formed is L-lysinylmethyl which is found in the specificity pocket. KGP uses cysteine to cleave proteins containing Lys-X. KGP always cuts after lysine residues <ref>PMID:21660656</ref>. The substrate is any peptide that contains a Lysine. Substrate XXLXX and the product would be XXL + XX. | The protein being studied in this article is <scene name='79/799598/Cartoon_view_of_kgp/3'>KGP</scene> <ref>PMID:25266723</ref>. This cysteine peptidase is a major virulence factor for the periodontopathogen ''Porphyromonas gingivalis''. KGP works by cleaving many constituents of human connective tissue which leads to decreased bacterial activity and chronic inflammation in the gums. It contains a catalytic triad of cysteine, histidine, and aspartic acid. The histidine and aspartic acid residues in the catalytic triad use acid base chemistry catalysis to form a covalent intermediate with the cysteine. The intermediate formed is L-lysinylmethyl which is found in the specificity pocket. KGP uses cysteine to cleave proteins containing Lys-X. KGP always cuts after lysine residues <ref>PMID:21660656</ref>. The substrate is any peptide that contains a Lysine. Substrate XXLXX and the product would be XXL + XX. | ||
==Disease== | ==Disease== | ||
- | ''Porphyromonas gingivalis'' is a Gram-Negative oral anaerobe that leads to periodontitis. It invades periodontal tissues, and evades the host defense mechanisms by a series of virulence factors, such as KGP, that deregulate innate immune and inflammatory responses. This bacteria and its products can enter circulation and contribute to the development of diabetes, cardiovascular disease, and rheumatoid arthritis. | + | ''Porphyromonas gingivalis'' is a Gram-Negative oral anaerobe that leads to periodontitis. It invades periodontal tissues, and evades the host defense mechanisms by a series of virulence factors, such as KGP, that deregulate innate immune and inflammatory responses. This bacteria and its products can enter circulation and contribute to the development of diabetes<ref>PMID: 24976875</ref>, cardiovascular disease<ref>PMID: 24949459</ref>, and rheumatoid arthritis<ref>PMID: 24068934</ref>. |
== Relevance == | == Relevance == | ||
Bacteria are typically beneficial to maintaining a healthy mouth, however, if they are a susceptible host they can become pathogenic <ref>PMID: 23985870</ref>. Once they become pathogenic they can invade tissues and lead to infection and disease. Resistant strains are currently responsible for half of all infections, and resistant pathogens infect over 2 million people annually in the United States<ref>PMID:24784427</ref>. The only way to keep up with these resistant pathogens is by developing new antimicrobials, but the pharmaceutical industry is failing to keep up<ref>PMID: 24784426</ref>. By studying KGP, scientists hope to find a suitable inhibitor to eliminate KGP activity, and thus prevent periodontal disease in humans. | Bacteria are typically beneficial to maintaining a healthy mouth, however, if they are a susceptible host they can become pathogenic <ref>PMID: 23985870</ref>. Once they become pathogenic they can invade tissues and lead to infection and disease. Resistant strains are currently responsible for half of all infections, and resistant pathogens infect over 2 million people annually in the United States<ref>PMID:24784427</ref>. The only way to keep up with these resistant pathogens is by developing new antimicrobials, but the pharmaceutical industry is failing to keep up<ref>PMID: 24784426</ref>. By studying KGP, scientists hope to find a suitable inhibitor to eliminate KGP activity, and thus prevent periodontal disease in humans. |
Revision as of 21:42, 20 November 2018
This Sandbox is Reserved from October 22, 2018 through April 30, 2019 for use in the course Biochemistry taught by Bonnie Hall at the Grand View University, Des Moines, IA USA. This reservation includes Sandbox Reserved 1456 through Sandbox Reserved 1470. |
To get started:
More help: Help:Editing |
Structure and Mechanism of Cysteine Peptidase Gingipain K (KGP), a Major Virulence Factor of Porphyromonas gingivitis in Periodontitis
|
References
- ↑ de Diego I, Veillard F, Sztukowska M, Guevara T, Potempa B, Pomowski A, Huntington JA, Potempa J, Gomis-Ruth FX. Structure and mechanism of cysteine peptidase Kgp, a major virulence factor of Porphyromonas gingivalis in periodontitis. J Biol Chem. 2014 Sep 29. pii: jbc.M114.602052. PMID:25266723 doi:http://dx.doi.org/10.1074/jbc.M114.602052
- ↑ Yongqing T, Potempa J, Pike RN, Wijeyewickrema LC. The lysine-specific gingipain of Porphyromonas gingivalis : importance to pathogenicity and potential strategies for inhibition. Adv Exp Med Biol. 2011;712:15-29. doi: 10.1007/978-1-4419-8414-2_2. PMID:21660656 doi:http://dx.doi.org/10.1007/978-1-4419-8414-2_2
- ↑ Tilakaratne A, Soory M. Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities. Open Dent J. 2014 May 30;8:109-24. doi: 10.2174/1874210601408010109. eCollection , 2014. PMID:24976875 doi:http://dx.doi.org/10.2174/1874210601408010109
- ↑ Kurita-Ochiai T, Yamamoto M. Periodontal pathogens and atherosclerosis: implications of inflammation and oxidative modification of LDL. Biomed Res Int. 2014;2014:595981. doi: 10.1155/2014/595981. Epub 2014 May 18. PMID:24949459 doi:http://dx.doi.org/10.1155/2014/595981
- ↑ Maresz KJ, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, Gawron K, Mizgalska D, Marcinska KA, Benedyk M, Pyrc K, Quirke AM, Jonsson R, Alzabin S, Venables PJ, Nguyen KA, Mydel P, Potempa J. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 2013 Sep;9(9):e1003627. doi: 10.1371/journal.ppat.1003627. Epub 2013, Sep 12. PMID:24068934 doi:http://dx.doi.org/10.1371/journal.ppat.1003627
- ↑ Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jorgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clement K, Dore J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506. PMID:23985870 doi:http://dx.doi.org/10.1038/nature12506
- ↑ May M. Drug development: Time for teamwork. Nature. 2014 May 1;509(7498):S4-5. doi: 10.1038/509S4a. PMID:24784427 doi:http://dx.doi.org/10.1038/509S4a
- ↑ Hede K. Antibiotic resistance: An infectious arms race. Nature. 2014 May 1;509(7498):S2-3. doi: 10.1038/509S2a. PMID:24784426 doi:http://dx.doi.org/10.1038/509S2a